Cancer typea | S ~ Dd | S ~ D + Ee | PS ~ Df | PS ~ D + Eg |
---|
Beta |
P
| Beta |
P
| Beta |
P
| Beta |
P
|
---|
bladder | 0.430 | 1.7 × 10− 3 | 0.082 | 0.68 | 0.354 | 9.4 × 10− 3 | 0.000 | 0.99 |
breast | −0.281 | 5.6 × 10− 3 | −0.620 | 2.8 × 10− 6 | − 0.287 | 4.8 × 10− 3 | − 0.50 | 1.4 × 10− 4 |
cervical | 0.281 | 0.19 | 0.017 | 0.96 | 0.278 | 0.20 | −0.063 | 0.84 |
lungb | −0.048 | 0.78 | −0.282 | 0.07 | −0.124 | 0.48 | −0.449 | 0.03 |
lungc | 0.511 | 0.13 | 0.077 | 0.88 | 0.385 | 0.25 | −0.190 | 0.70 |
head and neck | 0.160 | 0.42 | −0.067 | 0.85 | 0.284 | 0.16 | 0.065 | 0.85 |
stomach | −0.141 | 0.67 | −0.319 | 0.42 | −0.060 | 0.86 | −0.074 | 0.85 |
pancreas | −0.439 | 0.39 | −0.571 | 0.29 | −0.388 | 0.45 | −0.498 | 0.36 |
thyroid | 0.029 | 0.85 | −0.238 | 0.19 | 0.025 | 0.87 | −0.231 | 0.20 |
kidney | 0.323 | 0.17 | 0.14 | 0.59 | 0.292 | 0.21 | 0.105 | 0.69 |
- “a” Sample size for each cancer type: bladder (N = 286), breast (N = 734), cervical (N = 133), lung adenocarcinoma (N = 363), lung squamous carcinoma (N = 85), head and neck (N = 323), stomach (N = 66), pancreas (N = 90), thyroid (N = 333), kidney (N = 143). “b” and “c” refers to lung adenocarcinoma and lung squamous carcinoma, respectively. “d”: APOBEC-mutational signature ~ Germline APOBEC3A/B deletion; “e”: APOBEC-mutational signature ~ Germline APOBEC3A/B deletion + uc003awn + uc003awo + uc011aoc (Expression levels); “f”: Proportion of APOBEC-mutational signature ~ Germline APOBEC3A/B deletion; “g”: Proportion of APOBEC-mutational signature ~ Germline APOBEC3A/B deletion + uc003awn + uc003awo + uc011aoc (Expression levels); In association models: “S” refers to APOBEC-mutational signature; “D” refers to germline APOBEC3A/B deletion; “E” refers to isoform expression levels; “RS” refers to proportion APOBEC-mutational signature. The significance level at P = 0.005, corresponding to a threshold with a Bonferroni-correction of P = 0.05, given 10 tests